GPhA adds Francer as SVP, general counsel

WASHINGTON — The Generic Pharmaceutical Association (GPhA) announced Monday that Jeffrey K. Francer will be joining the organization as SVP and general counsel starting Nov. 14, reporting to GPhA president and CEO Chip Davis. 

 

"I am thrilled to have Jeff join the GPhA leadership team to serve as our General Counsel," said Chip Davis, President and CEO of GPhA. "With his valuable experience working with the FDA, Congress, and biopharmaceutical companies, Jeff will be a strong advocate for our industry as we tackle complex issues including drug affordability during the next presidential administration and beyond.”

 

Francer joins GPhA from the Pharmaceutical Research and Manufacturers of America (PhRMA), where he served as VP and senior counsel overseeing PhRMA’s advocacy on regulatory law. He has previously served as associate general counsel and U.S. compliance offer for Biogen, a role that followed his time as the Food and Drug Administration’s associate chief counsel. At the FDA Francer counseled agency leaders on drug and biologics regulation, including clinical trials, manufacturing and safety issues. 

 

"The challenges facing our nation to provide safe, effective, and affordable health care to patients have never been greater," Francer said. "Enhancing generic and biosimilar competition, as well as ensuring the FDA's timely review of generic drugs, will be critical to addressing the needs of patients, and I'm excited to devote my energy to this mission."